Tyra Biosciences Q2 net loss $45.6M; cash $353.9M; initial Ph2 data from SURF302 expected Sept 2026

Tyra Biosciences, Inc.

Net loss of $45.6M in Q2 2026 vs $28.1M in Q2 2025; R&D expenses rose to $39.2M from $24.3M.
Cash, cash equivalents and marketable securities of $353.9M as of June 30, 2026; runway into 2H 2028.
Initial Ph2 data from SURF302 (dabogratinib in IR NMIBC) expected September 2026; n>40 enrolled.
Initial Ph2 data from BEACH301 (achondroplasia) safety sentinel cohort including 5th dose level expected end of Q1 2027.
Appointed Jonathan Day as EVP, Clinical Development; amended ATM sales agreement for up to $250M additional shares.

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.